Background: Sulfonamide derivatives are of great attention due to their wide spectrum of biological activities. Sulfonamides conjugated with acetamide fragments exhibit antimicrobial and anticancer activities. The inhibition dihydrofolate reductase (DHFR) is considered as one of the most prominent mechanism though which sulfonamide derivatives exhibits antimicrobial and antitumor activities.
Introduction
Sulfonamides have attracted considerable deal of interest over past decades due to their broad and wide spectrum of biological activities which includes antibacterial [1] , antifungal [2] , hypoglycemic [3] , anti-thyroid [4] , diuretic [5, 6] and anti-HIV properties [7] . Recently, a large number of structurally novel sulfonamides have been reported to show substantial in vitro and in vivo antitumor activity [8] [9] [10] [11] [12] [13] [14] [15] . The anticancer activity is exerted by the sulfonamides through a wide range of mechanisms, such as cell cycle arrest in the G1 phase [16] , inhibition of carbonic anhydrase (CA) [17] , matrix metalloproteinase (MMPs) [18] , NADH oxidase [19] , cyclin-dependent kinase (CDK) [20] , methionine aminopeptidases (MetAPs) [21] , histone deacetylases (HDACs) [22] , binding to β-Tubulin, and disruption of microtubule assembly [23] .
On other hand, compounds with acetamide linkage exhibit variety of applications, which are well documented. The Lewis acid property of acetamides renders them useful as analytical reagents and in the preparation of a number of coordination complexes [24] . The acetamide functional group is responsible for antimicrobial [25, 26] , antioxidant [27, 28] , narcolepsy treatment [29] , anti-inflammatory [30, 31] , platelet aggregation inhibitory [32] , and urease inhibitory activities [33] . The acetamides and their analogues are also well studied as chemotherapeutic agents [34, 35] .
Dihydrofolate reductase (DHFR) is a key enzyme that catalyzes the NADPH-dependent reduction of 7,8-dihydrofolate (DHF) to 5,6,7,8- , which is the precursor of the co-factors required for the biosynthesis of purine nucleotides, thymidine (precursor for DNA replication) and several amino acids [36] . Thus, inhibition of DHFR can lead to the disruption of DNA synthesis and the death of the rapidly proliferating cells [36, 37] . In addition to this, bacteria also need DHFR to grow and multiply and hence inhibitors selective for bacterial against host DHFR have found application as antibacterial agents [38] . These two important aspects render DHFR enzyme as a key target for both antimicrobial and antitumor drug design.
The sulfonamide group conjugated with acetamides possessing different aryl, heteroaryl as well as alkyl substituents exhibits immense pharmacological potential, particularly sulfonamides containing short amine fragments exhibits encouraging anticancer activity [39] [40] [41] . This accounts for the growing interest in the synthesis, biological properties and structure activity relationships of sulfonamide-acetamide derivatives.
Based on these prior observations relating to the synthesis of sulfonamide derivatives [42, 43] and bioactive nitrogen-containing heterocyclic agents [44] [45] [46] [47] [48] we envisaged that sulfonamides bearing acetamide pharmacophores could be very efficient for antimicrobial and anticancer activity. In the present work, we report the synthesis of some novel sulfonamide-N
4
-acetamide derivatives and their evaluation of their cytotoxic activity against human lung carcinoma (A-549) and human breast carcinoma (MCF-7) cell lines.
Results and discussion

Chemistry
The present study deals with the design and synthesis of some acetamide derivatives having different aryl substituents (tails) conjugated with biologically active sulfonamide moiety in order to explore their combined effect on the antimicrobial and antitumor activities, and study their structure-activity relationship (SAR).
As the DHFR inhibition is considered as one of the most prominent mechanism for the antimicrobial and antitumor activities [49] [50] [51] , the synthesized compounds were intended to comply with the pharmacophore present in compounds that may act as DHFR inhibitors. The sulfonamide is attached to a scaffold, which is frequently a benzene ring, and a tail comprising of groups such as 2-(arylamino)acetamide or N-arylacetamide is attached to scaffold. The tail possesses a hydrophobic moiety, which is able to interact with the hydrophobic part of the active site and a hydrophilic linker which can interact with the hydrophilic part of the DHFR active site (Fig. 1 ). This pharmacophore was designed from the analysis of the DHFRs active site and from the structure of inhibitors were described in literature [52, 53] .
In this work, the starting key materials 4-(piperidin-1-ylsulfonyl)aniline (1a) and 4-(morpholin-4-ylsulfonyl) aniline (1b) were prepared accordingly as the reported method [42] , and were converted to the corresponding chloroacetamide derivatives 2a,b in excellent yields The target compounds 2-(arylamino)-N-(4-(piperidin-1-ylsulfonyl)phenyl)acetamides 5a-h and 2-(arylamino)-N-(4-(morpholino-sulfonyl)phenyl)acetamides 5i-p, were obtained in moderate to good yields (51-84%) by refluxing chloroacetamide derivatives 2a and 2b, respectively, with arylamines (namely; aniline, 4-methoxyaniline, 4-methylaniline, 4-chloroaniline, 4-bromoaniline, ethyl 4-aminobenzoate, 4-aminobenzoic acid, and 4-nitroaniline) in absolute ethanol for 3-5 h. (Scheme 1).
On the other hand, 2-chloro-N-arylacetamides 4a-h were easily prepared by the reaction of arylamines (namely; aniline, 4-methoxyaniline, 4-methylaniline, 4-chloroaniline, 4-bromoaniline, ethyl 4-aminobenzoate, 4-aminobenzoic acid, and 4-nitroaniline) with chloroacetyl chloride in DMF at room temperature.
Reaction of 2-chloro-N-arylacetamides 4a-h with sulfonamide derivatives 1a and 1b in ethanol under refluxing conditions afforded the target compounds N-aryl-2-(4-(piperidin-1-ylsulfonyl) phenylamino)-acetamides 6a-h and N-aryl-2-(4-(morpholinosulfonyl)-phenylamino)-acetamides 6i-p, respectively, in good to excellent yields (57-97%) (Scheme 1). The reactions were performed in the presence of catalytic amount of triethylamine as a basic catalyst with a reaction time of 4-6 h. The structures of all synthesized compounds 2a,b, 5a-p and 6a-p were well-established on the basis of FT-IR, 1 H-NMR, 13 C-NMR, and DEPT-135 data (c.f. "Experimental" section). The FT-IR spectra of compounds 5a-p displayed the presence of characteristic absorption bands H-NMR spectrum exhibited two singlet signals at 10.94 and 6.11 ppm for two NH protons. Two doublets at 8.24 and 6.87 ppm (J = 7.5 Hz) for the protons of 4-nitrophenyl moiety and two doublets at 7.84 and 7.35 ppm (J = 8.0 Hz) for aromatic CH's protons of the scaffold moiety were present. In addition, a singlet signal at 4.35 ppm for the tail methylene protons and two multiplets at 3.60 and 2.78 ppm for the morpholinyl ring protons were recorded.
Antimicrobial activity
The novel compounds were evaluated for antimicrobial activity against two strains of Gram-positive bacteria known as S. aureus (RCMB010010), and B. subtilis RCMB 015 (1) NRRL B-543, as well as two strains of Gram-negative bacteria namely E. coli (RCMB 010052) ATCC 25955, and P. vulgaris RCMB 004 (1) ATCC 13315, in addition to two types of fungi namely A. fumigatus (RCMB 002008), and C. albicans RCMB 005003 (1) ATCC 10231.
The result of the antimicrobial assay of the synthesized compounds is given in Table 1 and Fig. 2 . It is observed that some of the compounds showed higher antimicrobial activity compared to the reference drugs. These compounds have given the best results in the inhibition of different types of bacteria and fungi; compound 5h against the S. aureus, the zone of inhibition with ZOI value 26, compounds 5g, 5l, 6l and 6n against B. Subtili having ZOI value 25, compound 5c against E. coli with ZOI value 23, while, compound 6n against P. vulgaris having ZOI value 25. Moreover, compounds 5h, 5n, 5p, 6a, 6b, 6c, 6d, 6f, 6h, 6i, 6j, 6k, 6l, 6m, 6n and 6p against A. fumigatus, having (ZOI) values 25, 17, 30, 30, 21, 20, 17, 19, 20, 35, 33, 33, 32, 27, 30, 38; respectively. Furthermore, the following compounds 6a, 6d, 6h having ZOI value 22 while, compounds 6k and 6l having ZOI values 23, 26; respectively against C. Albicans. It is clearly evident from the antimicrobial results that the synthesized compounds 6l and 6n exhibit dual activities as promising antibacterial and antifungal agents.
From all the previous data, its be concluded that, the following compounds 5g, 5h, 5l, 6l and 6n are the highly active compounds which have antibacterial activity against strains of Gram-positive bacteria. While, compounds 5c and 6n showing activity against strains of Gram-negative bacteria. All compared to Gentamycin as antibacterial reference drug. Moreover, compounds 5h, 5n, 5p, 6a, 6b, 6c, 6d, 6f, 6h, 6i, 6j, 6k, 6l, 6m, 6n, 6p acted as antifungal agents compared to Ketoconazole as a reference drug.
In vitro anticancer activity
All new tested compounds were screened against human lung carcinoma (A-549) and breast carcinoma (MCF-7). The final result of evaluation were expressed as IC 50 (the required concentration which can inhibit 50% of cancer cells viability). Results are explained in Tables 2 and 3 . The reference control was 5-Fluorouracil (5-FU).
From the obtained results in Tables 2 and 3 Table 2 and Fig. 3 it is clear that, the cytotoxic activity order against cell line (A-549) having the following order: 5j > 5g > 5d
However, from data shown in Table 3 and Fig. 3 , we can concluded that, the cytotoxic activity order against cell line (MCF-7) is:
The previous biological screening results of the tested compounds lead to development of potential anticancer agents.
Docking and molecular modeling study
The best enzymes which involved in the improvement of anticancer and antimicrobial activity are thymidylate synthase and dihydrofolate reductase (DHFR) [50, 54] . In the present investigation, Molecular Operating Environment (MOE) [55] module was accomplished to vindicate the cytotoxic potency of all tested compounds. Furthermore, study of Molecular docking help in explanation of how compounds act through their reaction with the enzyme active sites. Docking was performed for the compounds 5a-5p and 6a-6p on the (DHFR) to predict their action as anticancer drugs (c.f. Additional file 1). The synthesized compounds show numerous interactions with DHFR enzyme. It's important to mention that compounds 6n, 5p, 5c, 5d, 6f and 6c could make their action via inhibition of the DHFR enzyme (Table 4 ). In Fig. 4 , the docking score energy for the newly synthesized compounds was indicated as the following order:
Docking of 5-Fluorouracil (5-FU) into DHFR
The docking studies at the active site showed presence of two hydrogen bond interactions as two oxygen atoms acted as hydrogen bond acceptors with Arg 52 and Arg 57 (3.13 Å and 2.96 Å) with binding energies of − 2.8 and
, respectively. Moreover, it indicated the presence of two ionic bond interactions that is between oxygen atom and amino acid residues Lys 32 and Arg 52 (3.14 Å and 3.05 Å) with binding energies of − 3.6 and − 4.1 kcal mol 5b  5c  5d  5e  5f  5g  5h  5i  5j  5k  5l  5m  5n  5o  5p  6a  6b  6c  6d  6e  6f  6g  6h  6i  6j  6k  6l  6m  6n 
Conclusion
We report herein the synthesis of some new series of 2-(arylamino)acetamides and N-arylacetamides bearing sulfonamide moieties. Most of these new compounds exhibited significant anticancer activity against human lung carcinoma (A-549) and human breast carcinoma (MCF-7) cell lines, when compared to 5-Fluorouracil as a reference drug. In addition, on antimicrobial evaluation; some of these synthesized compounds showed remarkable activity as antibacterial and antifungal agents. To the best of our knowledge, these multi-addressable properties of the new synthesized sulfonamides reported in this work will open a new era in the field of medicinal chemistry and can be considered as pharmacophores.
Experimental
Chemistry
General methods
All solvents used purchased from Sigma-Aldrich are spectroscopic grade and used without further purifications. Melting points were determined on a Stuart SMP3 melting point apparatus and are uncorrected. FT-IR spectra were recorded on a Shimadzu IR-3600 FT-IR spectrometer in KBr pellets. NMR spectra were acquired on a Bruker N-(4-(piperidin-1-ylsulfonyl) 5a  5b  5c  5d  5e  5f  5g  5h  5i  5j  5k  5l  5m  5n  5o  5p  6a  6b  6c  6d  6e  6f  6g  6h  6i  6j  6k  6l  6m  6n  6o  6p Fig. 4 The docking score energy of the tested synthesized compounds N-aryl-2-(4-(piperidin-1-ylsulfonyl)phenyl-amino)  acetamides 6a-h and N-aryl-2-(4-(morpholinosulfonyl) 
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phenylamino)-acetamides 6i-p
In a round bottomed flask, 2-chloro-N-arylacetamide 4a-h (0.001 mol), sulfonamide 1a,b (0.001 mol) and triethylamine (0.1 mL) in absolute ethanol (20 mL) was refluxed for 4-6 h. The reaction mixture was cooled to room temperature, the solid obtained was filtered, washed with cold ethanol, dried and recrystallized from ethanol to give the titled products 6a-p and 6i-p. Piperidin-1-ylsulfonyl) 
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Antimicrobial screening
All microbial strains were provided from culture collection of the Regional Center for Mycology and Biotechnology (RCMB), Al-Azhar University, Cairo, Egypt. The antimicrobial activity was evaluated by disc-agar diffusion method [62] [63] [64] using Mueller-Hinton Agar. Activation of various strains of bacteria occurred by using a loop that full of bacterial strain in the broth and incubated for 24 h at 37 °C. Furthermore, 0.1 mL of the suspension of strains was poured on the agar, spread well and left to solidify. Moreover, using a sterile cork, about 0.9 cm cut was made and were filled completely with the tested compound solution. The wells were incubated at 37 °C for 24 h. Each assay was done in triplicate. ZOI was determined using the mean value. Tested compound giving high ZOI value reflecting its significant antibacterial activity. Efficacy of the novel compounds was measured against different strains of Gram positive and Gram-negative bacteria, also evaluated against different fungal strains. The Gram-positive organisms that were used for culture sensitivity include S. aureus (RCMB010010), and B. subtilis RCMB 015 (1) NRRL B-543, on the other hand, the Gram-negative organisms that were used for culture sensitivity include E. coli (RCMB 010052) ATCC 25955, and P. vulgaris RCMB 004 (1) ATCC 13315. The fungal strains that were used include A. fumigatus (RCMB 002008), and C. albicans RCMB 005003 (1) ATCC 10231. Different antibiotics were used as a reference for evaluating the antimicrobial activity of novel compounds. Gentamycin and Ketoconazole were used as a reference antibiotic for assessing the antimicrobial activity of the novel compounds against bacterial and fungal strains, respectively.
In vitro anticancer screening
The cell lines were purchased from the American Type Culture collection and their accession number as follows: A-549 (ATCC CCL-185 ™ ) lung carcinoma cell line and MCF-7 (ATCC HTB-22 ™ ) breast adenocarcinoma cell line.
Cytotoxic activity screening was performed at Regional Center for Mycology and Biotechnology, AlAzhar University, according to the suggested method of Skehan et al. [65] . Exponentially, cells were placed in 10 4 cells/well for 24 h, and then add fresh medium which containing different concentration of the tested sample. Serial two-fold dilutions of the tested sample were added using a multichannel pipette. Moreover, all cells were cultivated at 37 °C, 5% CO 2 and 95% humidity. Also, incubation of control cells occurred at 37 °C. However, after incubation for 24 h different concentrations of sample (500, 250, 125, 62.50, 31.25, 15.60, 7.80, 3.90, 2, 1 and 0 µg L −1 ) were added and continued the incubation for 48 h, then, add the crystal violet solution 1% to each well for 0.5 h to examine viable cells. Rinse the wells using water until no stain. After that, add 30% glacial acetic acid to all wells with shaking plates on Microplate reader (TECAN, Inc.) to measure the absorbance, using a test wavelength of 490 nm. Besides, compare the treated samples with the control cell. The cytotoxicity was estimated by IC 50 in µM; the concentration that inhibits 50% of growth of cancer cell.
